Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Accumulated Depreciation (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Accumulated Depreciation for 7 consecutive years, with $21.3 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation rose 28.3% to $21.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.3 million through Dec 2025, up 28.3% year-over-year, with the annual reading at $21.3 million for FY2025, 28.3% up from the prior year.
  • Accumulated Depreciation for Q4 2025 was $21.3 million at 4D Molecular Therapeutics, up from $20.1 million in the prior quarter.
  • The five-year high for Accumulated Depreciation was $21.3 million in Q4 2025, with the low at $4.2 million in Q1 2021.
  • Average Accumulated Depreciation over 5 years is $11.2 million, with a median of $10.3 million recorded in 2023.
  • The sharpest move saw Accumulated Depreciation surged 61.32% in 2023, then grew 28.3% in 2025.
  • Over 5 years, Accumulated Depreciation stood at $5.3 million in 2021, then soared by 45.13% to $7.7 million in 2022, then soared by 54.4% to $11.9 million in 2023, then soared by 39.0% to $16.6 million in 2024, then increased by 28.3% to $21.3 million in 2025.
  • According to Business Quant data, Accumulated Depreciation over the past three periods came in at $21.3 million, $20.1 million, and $18.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.